Rani Therapeutics 的股价在与 Chugai 合作开发口服生物药物后飙升 170%，预付 $10M 和高达 $1.085B 的潜在付款。 Rani Therapeutics' stock surged 170% after partnering with Chugai to develop oral biologic drugs, securing $10M upfront and up to $1.085B in potential payments.

在宣布与Chugai制药公司合作利用Rani的RaniPill技术开发一种用于稀有疾病的口服生物药物后, Rani 治疗药物库存猛增170 % 至 1.24美元。 Rani Therapeutics stock jumped over 170% to $1.24 after announcing a collaboration with Chugai Pharmaceutical to develop an oral biologic drug for rare diseases using Rani’s RaniPill technology. 这笔交易包括一笔1 000万美元的先期付款和潜在的里程碑付款,总额达1.75亿美元,Chugai持有将方案扩大到另外五个方案的备选方案,可能将价值增加到10.85亿美元。 The deal includes a $10 million upfront payment and potential milestone payments totaling up to $175 million, with Chugai holding options to expand to five additional programs, possibly increasing the value to $1.085 billion. 同时,Rani筹集了6 030万美元的私人资金,预计资金将支持2028年的业务。 Concurrently, Rani raised $60.3 million in private financing, with funds expected to support operations through 2028.